Publications 2024

Guldvik IJ, Ramberg H, Kristensen G, Røder A, Mills IG, Lilleby W, Taskén KA (2024)
Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy
World J Urol, 42 (1), 95
DOI 10.1007/s00345-024-04787-8, PubMed 38386171

Lilleby W, Kishan A, Geinitz H (2024)
Acute and long-term toxicity in primary hypofractionated external photon radiation therapy in patients with localized prostate cancer
World J Urol, 42 (1), 41
DOI 10.1007/s00345-023-04714-3, PubMed 38244053

Tulipan A, Kratochwil C, Lilleby J, Lilleby W (2024)
A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer
Urol Case Rep, 54, 102752
DOI 10.1016/j.eucr.2024.102752, PubMed 38779691

Publications 2023

Lilleby W, Seierstad T, Inderberg EM, Hole KH (2023)
Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring
Int J Cancer, 152 (10), 2166-2173
DOI 10.1002/ijc.34448, PubMed 36715014

Publications 2022

Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM (2022)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827

Gongora M, Stranne J, Johansson E, Bottai M, Thellenberg Karlsson C, Brasso K, Hansen S, Jakobsen H, Jäderling F, Lindberg H, Lilleby W, Meidahl Petersen P, Mirtti T, Olsson M, Rannikko A, Røder MA, Henrik Vincent P, Akre O (2022)
Characteristics of Patients in SPCG-15-A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer
Eur Urol Open Sci, 41, 63-73
DOI 10.1016/j.euros.2022.04.013, PubMed 35813256

Guldvik IJ, Braadland PR, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, Røder A, Schlomm T, Berge V, Eri LM, Lilleby W, Mills IG, Taskén KA (2022)
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
Eur Urol Open Sci, 45, 68-75
DOI 10.1016/j.euros.2022.09.002, PubMed 36353660

Ryg U, Seierstad T, Nilsen LB, Hellebust TP, Djupvik LH, Gustafson H, Hydal J, Kishan AU, Hole KH, Lilleby W (2022)
A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome
Front Oncol, 12, 861127
DOI 10.3389/fonc.2022.861127, PubMed 35463376

Switlyk MD, Lilleby W (2022)
The Classic Form of Progressive Multifocal Leukoencephalopathy in Advanced Prostate Cancer: a Case Report
SN Comprehensive Clinical Medicine, 4 (1), 43
DOI 10.1007/s42399-022-01125-0, PublikaID 393

Publications 2021

Aljabri B, Lilleby W, Switlyk MD, Tafjord G (2021)
Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
Urol Case Rep, 37, 101648
DOI 10.1016/j.eucr.2021.101648, PubMed 33868933

Guldvik IJ, Ekseth L, Kishan AU, Stensvold A, Inderberg EM, Lilleby W (2021)
Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer
J Pers Med, 11 (7)
DOI 10.3390/jpm11070605, PubMed 34206815

Hernes E, Revheim ME, Hole KH, Tulipan AJ, Strømme H, Lilleby W, Seierstad T (2021)
Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis
PET Clin, 16 (2), 147-165
DOI 10.1016/j.cpet.2020.12.001, PubMed 33648661

Nakken S, Lilleby W, Switlyk MD, Knudsen KE, Lilleby O, Zhao S, Kaveh F, Ekstrøm PO, Urbanucci A, Hovig E (2021)
The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology
J Pers Med, 11 (5)
DOI 10.3390/jpm11050330, PubMed 33922147

Seierstad T, Hole KH, Tulipan AJ, Strømme H, Lilleby W, Revheim ME, Hernes E (2021)
¹⁸F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard: A Systematic Review
PET Clin, 16 (2), 167-176
DOI 10.1016/j.cpet.2020.12.012, PubMed 33648662

Tryggestad AMA, Axcrona K, Axcrona U, Bigalke I, Brennhovd B, Inderberg EM, Hønnåshagen TK, Skoge LJ, Solum G, Saebøe-Larssen S, Josefsen D, Olaussen RW, Aamdal S, Skotheim RI, Myklebust TÅ, Schendel DJ, Lilleby W, Dueland S, Kvalheim G (2021)
Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
Prostate, 82 (2), 245-253
DOI 10.1002/pros.24267, PubMed 34762317

Publications 2020

Deek M, Lilleby W, Vaage V, Hole KH, DeWeese T, Stensvold A, Tran P, Seierstad T (2020)
Impact of radiation dose on recurrence in high-risk prostate cancer patients
Prostate, 80 (15), 1322-1327
DOI 10.1002/pros.24059, PubMed 33258482

Fosså SD, Aas K, Müller C, Jerm MB, Tandstad T, Lilleby W, Kvåle R, Gulbrandsen J, Haug E, Myklebust TA (2020)
Definitive radiotherapy for prostate cancer in Norway 2006-2015: Temporal trends, performance and survival
Radiother Oncol, 155, 33-41
DOI 10.1016/j.radonc.2020.10.022, PubMed 33096165

Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG (2020)
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
Eur Urol Open Sci, 21, 51-60
DOI 10.1016/j.euros.2020.08.007, PubMed 34337468

Ryg U, Lilleby W, Hole KH, Lund-Iversen M, Switlyk MD (2020)
Local Recurrence of Prostate Cancer to the Intersphincteric Space: A Case Report
Urology, 140, 18-21
DOI 10.1016/j.urology.2020.03.009, PubMed 32199872

Publications 2019

Lilleby O, Hernes E, Lilleby W (2019)
Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
Urol Case Rep, 27, 100992
DOI 10.1016/j.eucr.2019.100992, PubMed 31453108

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM et al. (2019)
Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis
Eur Urol, 77 (1), 3-10
DOI 10.1016/j.eururo.2019.03.022, PubMed 30992160

Switlyk MD, Salberg UB, Geier OM, Vlatkovic L, Lilleby W, Lyng H, Seierstad T (2019)
PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings
AJR Am J Roentgenol, 212 (6), 1206-1214
DOI 10.2214/AJR.18.20743, PubMed 30888866

Publications 2018

Hayman J, Hole KH, Seierstad T, Perin J, DeWeese TL, Tran PT, Lilleby W (2018)
Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Urol Oncol, 37 (4), 289.e19-289.e26
DOI 10.1016/j.urolonc.2018.09.016, PubMed 30446451

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV et al. (2018)
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer
JAMA, 319 (9), 896-905
DOI 10.1001/jama.2018.0587, PubMed 29509865

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM et al. (2018)
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study
Int J Radiat Oncol Biol Phys, 101 (4), 883-888
DOI 10.1016/j.ijrobp.2018.03.060, PubMed 29976500

Stranne J, Brasso K, Brennhovd B, Johansson E, Jäderling F, Kouri M, Lilleby W, Meidahl Petersen P, Mirtti T, Pettersson A, Rannikko A, Thellenberg C, Akre O (2018)
SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer
Scand J Urol, 52 (5-6), 313-320
DOI 10.1080/21681805.2018.1520295, PubMed 30585526

Tulipan AJ, Hole KH, Vlatkovic L, Revheim ME, Reijnen JS, Willoch F, Seierstad T, Lilleby W (2018)
Localization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard
Acta Radiol, 60 (8), 1028-1038
DOI 10.1177/0284185118810977, PubMed 30379559

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W (2018)
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
Radiother Oncol, 132, 211-217
DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241

Publications 2017

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
Cancer Immunol Immunother, 66 (7), 891-901
DOI 10.1007/s00262-017-1994-y, PubMed 28391357

Publications 2016

Lilleby W, Stensvold A, Dahl AA (2016)
Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer
Acta Oncol, 55 (7), 807-13
DOI 10.3109/0284186X.2015.1127417, PubMed 26959297

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R (2016)
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA
Clin Nutr, 36 (3), 672-679
DOI 10.1016/j.clnu.2016.06.014, PubMed 27406859

Publications 2015

Lilleby W, Narrang A, Tafjord G, Vlatkovic L, Russnes KM, Stensvold A, Hole KH, Tran P, Eilertsen K (2015)
Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Radiat Oncol, 10, 232
DOI 10.1186/s13014-015-0540-3, PubMed 26577452

Lilleby W, Raabe NK, Normann M (2015)
[Re: The problematical prostate cancer]
Tidsskr Nor Laegeforen, 135 (11), 1009
DOI 10.4045/tidsskr.15.0593, PubMed 26080763

Lilleby W, Vlatkovic L, Meza-Zepeda LA, Revheim ME, Hovig E (2015)
Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report
J Med Case Rep, 9, 281
DOI 10.1186/s13256-015-0749-7, PubMed 26654961

Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W, Fosså SD, Thorsen L (2015)
Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy
Acta Oncol, 54 (10), 1805-13
DOI 10.3109/0284186X.2015.1037008, PubMed 25927504

Raabe NK, Normann M, Lilleby W (2015)
Low-dose-rate brachytherapy for low-grade prostate cancer
Tidsskr Nor Laegeforen, 135 (6), 548-52
DOI 10.4045/tidsskr.13.1404, PubMed 25806763

Solberg A, Angelsen A, Berge V, Lilleby W, Iversen J, Klepp O, Brennhovd B, Johannessen D, Nygård Y, Larsen K, Stensvold A (2015)
[Re: Different guidelines for treatment of prostate cancer]
Tidsskr Nor Laegeforen, 135 (12-13), 1105
DOI 10.4045/tidsskr.15.0652, PubMed 26130530

Publications 2014

Lilleby W, Stensvold A, Dahl AA (2014)
Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up
Acta Oncol, 53 (10), 1380-9
DOI 10.3109/0284186X.2014.916042, PubMed 24844918

Publications 2013

Lilleby W, Stensvold A, Dahl AA (2013)
Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life
Prostate, 73 (10), 1038-47
DOI 10.1002/pros.22651, PubMed 23532709

Lilleby W, Stensvold A, Mills IG, Nesland JM (2013)
Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients
Int J Cancer, 133 (1), 149-55
DOI 10.1002/ijc.28002, PubMed 23280694

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
Int J Radiat Oncol Biol Phys, 87 (4), 753-60
DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332

Publications 2012

Stensvold A, Dahl AA, Brennhovd B, Småstuen MC, Fosså SD, Lilleby W, Steinsvik A, Axcrona K, Smeland S (2012)
Bother problems in prostate cancer patients after curative treatment
Urol Oncol, 31 (7), 1067-78
DOI 10.1016/j.urolonc.2011.12.020, PubMed 22341412

Publications 2011

Lilleby W, Solca F, Roe K (2011)
Radiotherapy and inhibition of the EGF family as treatment strategies for prostate cancer: combining theragnostics with theragates
Oncol. Rev., 5 (2), 119-128
DOI 10.1007/s12156-010-0070-z

Lilleby W, Tafjord G, Raabe NK (2011)
Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer
Int J Radiat Oncol Biol Phys, 83 (3), 933-9
DOI 10.1016/j.ijrobp.2011.08.028, PubMed 22138456

Lilleby W, Willoch F, Stensvold A (2011)
Detection of prostate cancer relapse with PET/CT using a novel radiotracer
Acta Oncol, 51 (3), 397-9
DOI 10.3109/0284186X.2011.614638, PubMed 21936756

Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fosså SD, Lilleby W, Axcrona K, Smeland S (2011)
Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones
Prostate, 72 (6), 668-76
DOI 10.1002/pros.21470, PubMed 21809351

Publications 2010

Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W (2010)
Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma
Clin Oncol (R Coll Radiol), 23 (5), 339-43
DOI 10.1016/j.clon.2010.11.006, PubMed 21134733

Stensvold A, Dahl AA, Fosså SD, Axcrona K, Lilleby W, Brennhovd B, Smeland S (2010)
Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center
Acta Oncol, 50 (3), 408-14
DOI 10.3109/0284186X.2010.492236, PubMed 20586661

Publications 2009

Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH (2009)
Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
Clin Exp Metastasis, 26 (5), 485-96
DOI 10.1007/s10585-009-9248-9, PubMed 19294521

Fosså SD, Egey A, Haukaas SA, Angelsen A, Klepp O, Berge V, Axcrona K, Lilleby W (2009)
[Incorrect about hormone treatment in prostatic cancer]
Tidsskr Nor Laegeforen, 129 (5), 429
DOI 10.4045/tidsskr.08.0649, PubMed 19247406

Publications 2008

Berg A, Bruland ØS, Fosså SD, Nesland JM, Berner A, Schirmer C, Lilleby W (2008)
Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer
Prostate, 68 (15), 1607-14
DOI 10.1002/pros.20826, PubMed 18655095

Raabe NK, Lilleby W, Tafjord G, Aström L (2008)
[High dose rate brachytherapy in prostate cancer in Norway]
Tidsskr Nor Laegeforen, 128 (11), 1275-8
PubMed 18511969

Steinsvik EA, Fosså SD, Lilleby W, Eilertsen K (2008)
Fertility issues in patients with prostate cancer
BJU Int, 102 (7), 793-5
DOI 10.1111/j.1464-410X.2008.07739.x, PubMed 18489529

Publications 2007

Berg A, Berner A, Lilleby W, Bruland ØS, Fosså SD, Nesland JM, Kvalheim G (2007)
Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy
Int J Cancer, 120 (8), 1603-9
DOI 10.1002/ijc.22488, PubMed 17230512

Berg A, Lilleby W, Bruland OS, Fosså SD (2007)
10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy
Int J Radiat Oncol Biol Phys, 69 (4), 1074-83
DOI 10.1016/j.ijrobp.2007.04.031, PubMed 17703896

Lilleby W (2007)
Use of bisphosphonates in advanced prostate cancer: Current status
Indian J Urol, 23 (1), 54
DOI 10.4103/0970-1591.30268, PubMed 19675764

Lilleby W, Axcrona K, Alfsen GC, Urnes T, Hole KH (2007)
Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate
Acta Oncol, 46 (8), 1195-7
DOI 10.1080/02841860701367886, PubMed 17851841

Publications 2006

Lilleby W, Hernes E, Waehre H, Raabe N, Fosså SD (2006)
[Treatment of hormone-resistant prostate cancer]
Tidsskr Nor Laegeforen, 126 (21), 2798-801
PubMed 17086220

Publications 2005

Bassarova AV, Nesland JM, Sedloev T, Lilleby W, Hristova SL, Trifonov DY, Torlakovic E (2005)
Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53
Int J Surg Pathol, 13 (3), 239-46
DOI 10.1177/106689690501300302, PubMed 16086078

Lilleby W, Fosså SD (2005)
Chemotherapy in metastatic renal cell cancer
World J Urol, 23 (3), 175-9
DOI 10.1007/s00345-004-0469-x, PubMed 15726382

Lilleby W, Sudbø J, Fosså SD (2005)
[Biology and treatment options during the development of prostate cancer]
Tidsskr Nor Laegeforen, 125 (5), 571-4
PubMed 15776028

Torlakovic E, Lilleby W, Berner A, Torlakovic G, Chibbar R, Furre T, Fosså SD (2005)
Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma
Int J Cancer, 117 (3), 381-6
DOI 10.1002/ijc.21174, PubMed 15900599

Publications 2003

Brustugun OT, Nome O, Bruland S ØS, Ottestad L, Lilleby W (2003)
[Breast cancer patients' assessment of waiting time before radiotherapy]
Tidsskr Nor Laegeforen, 123 (12), 1685-6
PubMed 12821991

Fosså SD, Lilleby W, Waehre H, Berner A, Torlakovic G, Paus E, Olsen DR (2003)
Definitive radiotherapy of prostate cancer: the possible role of staging lymphadenectomy
Int J Radiat Oncol Biol Phys, 57 (1), 33-41
DOI 10.1016/s0360-3016(03)00428-0, PubMed 12909213

Lilleby W (2003)
Definitive external beam radiotheraphy of patients with prostate cancer: prognostic parameters, quality of life and outcome
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 116, 1 b. (flere pag.)
BIBSYS 031497195, ISBN 82-8072-080-4

Lilleby W, Dale E, Olsen DR, Gude U, Fosså SD (2003)
Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose
Acta Oncol, 42 (1), 10-4
DOI 10.1080/0891060310002177, PubMed 12665325

Lilleby W, Nesland JM, Fosså SD, Torlakovic G, Waehre H, Kvalheim G (2003)
The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer
Int J Cancer, 103 (1), 91-6
DOI 10.1002/ijc.10780, PubMed 12455058

Publications 2002

Fosså A, Lilleby W, Fosså SD, Gaudernack G, Torlakovic G, Berner A (2002)
Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy
Int J Cancer, 99 (1), 100-5
DOI 10.1002/ijc.10286, PubMed 11948499

Torlakovic E, Lilleby W, Torlakovic G, Fosså SD, Chibbar R (2002)
Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score
Hum Pathol, 33 (6), 646-51
DOI 10.1053/hupa.2002.124033, PubMed 12152165

Publications 2001

Lilleby W, Paus E, Skovlund E, Fosså SD (2001)
Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer
Prostate, 46 (2), 126-33
DOI 10.1002/1097-0045(20010201)46:2<126::aid-pros1016>3.0.co;2-7, PubMed 11170140

Lilleby W, Torlakovic G, Torlakovic E, Skovlund E, Fosså SD (2001)
Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy
Cancer, 92 (2), 311-9
DOI 10.1002/1097-0142(20010715)92:2<311::aid-cncr1324>3.0.co;2-h, PubMed 11466684

Publications 2000

Lilleby W, Fosså SD, Knutsen BH, Abildgaard A, Skovlund E, Lien HH (2000)
Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation
Radiother Oncol, 57 (2), 195-200
DOI 10.1016/s0167-8140(00)00219-x, PubMed 11054523

Publications 1999

Lilleby W, Fosså SD, Waehre HR, Olsen DR (1999)
Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy
Int J Radiat Oncol Biol Phys, 43 (4), 735-43
DOI 10.1016/s0360-3016(98)00475-1, PubMed 10098428

Lilleby W, Olsen DR, Foss a SD (1999)
Comparison of radiation side-effects in prostate cancer
Lancet, 353 (9162), 1443
DOI 10.1016/s0140-6736(05)75969-9, PubMed 10227249